Eli Lilly and

Yahoo Finance • 11 days ago

In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s

Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly’s lead in obesity and diabetes treatment should hold for years. Continue Reading... Full story

Yahoo Finance • 11 days ago

So Long, Warren. Buffett Leaves Astonishing Gains As He Steps Down As CEO.

Warren Buffett steps away as CEO of Berkshire Hathaway, leaving behind a stock near all-time highs and with a market capitalization of more than $1 trillion. Continue Reading... Full story

Yahoo Finance • 11 days ago

All J.P. Morgan's top stock picks for 2026

[Countdown to 2026. Loading year from 2025 to 2026. New year start concept.] SmileStudioAP J.P. Morgan identifies specific traits that define their Best Ideas for 2026. These companies typically possess: * Strong Financial Health: Rob... Full story

Yahoo Finance • 11 days ago

Could This Potential Move Boost Eli Lilly's Prospects?

Key Points Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the immunology market. There are plenty of reasons to like the stock beyond this development. 10 stocks we like... Full story

Yahoo Finance • 11 days ago

Pfizer and GSK Lead 2026 U.S. Drug Price Hikes

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) are among the top drugmakers planning price increases for hundreds of branded medicines in the U.S. next year, according to a Tuesday report from 3... Full story

Yahoo Finance • 11 days ago

Vanda Jumps 21% After FDA Approves Motion Sickness Therapy

This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S. Food and Drug Administration approved its motion sickness therapy Nereus, also known as tradipitant, a dr... Full story

Yahoo Finance • 11 days ago

Dow Jones Futures Fall On 2025's Final Day; Eli Lilly, Shopify Forge Buy Points

The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points. Continue Reading... Full story

Yahoo Finance • 11 days ago

Dow Jones Futures Fall On New Year's Eve; Eli Lilly, Shopify Forge Buy Points

The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points. Continue Reading... Full story

Yahoo Finance • 12 days ago

Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026.Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in it... Full story

Yahoo Finance • 12 days ago

Dow Jones Futures: Market Holds Near Highs With 2025 Ending; Eli Lilly, Shopify Forge New Buy Points

The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points. Continue Reading... Full story

Yahoo Finance • 12 days ago

Eli Lilly and Novo Nordisk Shares Dip After Cut Obesity Drug Prices in China

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) saw their shares dip about 0.5% on Tuesday after the companies lowered prices for their obesity treatments in China. The Danish pharmaceutical com... Full story

Yahoo Finance • 12 days ago

Should You Buy the iShares S&P 500 ETF Before 2026, Even With the Stock Market at an All-Time High?

Key Points The S&P 500 is a diversified index featuring 500 stocks from 11 different economic sectors. The index has delivered a compound annual return of 10.5% since its inception in 1957. The iShares Core S&P 500 ETF is a very low-cost... Full story

Yahoo Finance • 12 days ago

Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China

This article first appeared on GuruFocus. Novo Nordisk (NOVO, Financials) and Eli Lilly (LLY, Financials) are reducing prices for their leading obesity treatments, Wegovy and Mounjaro, in China to strengthen market share in the world's mo... Full story

Yahoo Finance • 12 days ago

Novo and Lilly cut prices of weight-loss drugs in China

STORY: Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China.Novo did not give details on the new prices.But media outlet Yicai reported earlier that list prices for the two highest... Full story

Yahoo Finance • 13 days ago

Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways

Newark, DE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The term "best" reflects common consumer search phrasing and is used here to explore access pathways and evaluation criteria, not to endorse or rank any specific product or provider. This ana... Full story

Yahoo Finance • 13 days ago

CMS unveils payment model to boost GLP-1 access for Medicare Part D, Medicaid

[Two packages of 5 dosing pens each of a fictitious Semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. Fictitious package design] aprott * CMS has unveiled a volun... Full story

Yahoo Finance • 13 days ago

UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026

Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks. Continue Reading... Full story

Yahoo Finance • 13 days ago

This Beaten-Down Stock Just Jumped By 8%. Time to Buy?

Key Points Pharmaceutical giant Novo Nordisk just earned approval for an oral version of Wegovy. This could help improve its position in the increasingly competitive weight loss market. Despite some headwinds, there are several reasons to... Full story

Yahoo Finance • 13 days ago

The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug

The recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s NVO oral obesity pill, Wegovy, marks a significant turning point in the fiercely competitive weight-loss drug market. This pill, the first GLP-1 tablet specifica... Full story

Yahoo Finance • 13 days ago

The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.

Key Points Novo Nordisk's CagriSema could be a brand new growth driver for the company. Eli Lilly's orforglipron is breaking into a new, lucrative market. One of these companies should lead this market, but both could be attractive buys.... Full story